Clinical implications of converting stable haemodialysis patients from subcutaneous to intravenous administration of darbepoetin alfa

Nephrology Dialysis Transplantation

Volumn 21, Issue 5, 2006, Pages 1312-1316

  Aarup, Michael ^a   Bryndum, Julie ^a   Dieperink, Hans ^a   Joffe, Preben ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Darbepoetin alfa; Haemodialysis; Haemoglobin; Renal anaemia; Route of administration

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; FERRITIN; HEMOGLOBIN; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PARATHYROID HORMONE;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ANEMIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSSOVER PROCEDURE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; FEMALE; FERRITIN BLOOD LEVEL; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEMOGLOBIN DETERMINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PARATHYROID HORMONE BLOOD LEVEL; PRIORITY JOURNAL; PROBABILITY; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RETICULOCYTE COUNT; STATISTICAL SIGNIFICANCE;

AGED; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ERYTHROPOIETIN; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBINS; HUMANS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PROBABILITY; PROSPECTIVE STUDIES; REFERENCE VALUES; RENAL DIALYSIS; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 33646181084     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfk048     Document Type: Article

References (10)

1. Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer 2001; 84 [Suppl 1]: 3-10
2. Macdougall IC, Gray SJ, Elston O et al. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrology 1999; 10: 2392-2395
3. Brunkhorst R, Bommer J, Braun J et al. Darbepoetin alfa effectively maintains haemoglobin concentration at extended dose intervals relative to intravenous or subcutaneous recombinant human erythropoietin in dialysis patients. Nephrol Dial Transplant 2004; 19: 1224-1230
4. Vanrenterghem Y, Bárány P, Mann JFE et al. Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with epoetin in dialysis patients. Kidney Int 2002; 62: 2167-2175
5. Locatelli F, Olivares J, Walker R et al. Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency. Kidney Int 2001; 60: 741-747
6. Motulsky H. Intuitive Biostatistics. Oxford University Press, New York, 1995
7. Locatelli F, Canaud B, Giacardy F et al. Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo). Nephrol Dial Transplant 2003; 18: 362-369
8. Louis TA, Lavori PW, Bailar JC,III, Polansky M. Crossover and self-controlled designs in clinical research. N Engl J Med 1984; 310: 24-31
9. Cervelli MJ, Gray N, McDonald S, Gentgall MG, Disney APS. Randomized cross-over comparison of intravenous and subcutaneous darbepoetin dosing efficiency in haemodialysis patients. Nephrology 2005; 10: 129-135
10. Schellekens H. Factors influencing the immunogenicity of therapeutic proteins. Nephrol Dial Transplant 2005; 20 [Suppl 6]: Vi3-vi9